kin-15 Antibody

What is Cytokeratin 15 and what role does it play in epithelial tissues?

Cytokeratin 15 (K15) is a type I (acidic) keratin protein that belongs to the keratin gene family. These intermediate filament proteins are responsible for maintaining the structural integrity of epithelial cells. K15 is specifically characterized as a type I cytoskeletal keratin, with the protein encoded by the KRT15 gene located on chromosome 17q21.2 in humans . Several protein aliases exist for this molecule including CK-15, K15, keratin 15, keratin complex 1, acidic, gene 15, and keratin, type I cytoskeletal 15 .

The functional significance of Cytokeratin 15 lies in its contribution to the mechanical stability of epithelial tissues. It forms heterodimeric pairs with type II keratins, creating the structural foundation of the intermediate filament cytoskeleton in epithelial cells. This provides resistance against mechanical stress while maintaining cellular shape and tissue integrity. K15 expression is particularly important in specific epithelial stem cell populations, making it a valuable marker for research into epithelial stem cell identification and characterization.

What applications are Cytokeratin 15 antibodies most commonly used for?

Cytokeratin 15 antibodies find utility across multiple experimental applications in research settings:

• Immunohistochemistry (IHC-P): K15 antibodies are frequently employed to detect and visualize K15-expressing cells in formalin-fixed, paraffin-embedded tissue sections. This application is particularly valuable for identifying epithelial stem cell populations in tissues like the hair follicle bulge region .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Researchers utilize K15 antibodies to localize and study the expression pattern of K15 in cultured cells, providing insights into cytoskeletal organization and cellular identity .

• Western blotting: This application allows researchers to determine K15 protein expression levels and assess antibody specificity. The MA5-11344 monoclonal antibody clone (LHK15) has demonstrated effectiveness in Western blot applications for detecting K15 protein in multiple species .

When selecting an antibody for these applications, researchers should consider factors such as clone specificity, species reactivity, and validated application protocols to ensure optimal experimental outcomes.

How can researchers validate the specificity of Cytokeratin 15 antibodies?

Validating antibody specificity is a critical step in ensuring experimental reliability. For Cytokeratin 15 antibodies, researchers should implement multiple validation approaches:

• Blocking peptide assays: Using the original antigen peptide (such as a 17-mer synthetic peptide from the C-terminus of human cytokeratin 15) to pre-adsorb the antibody before application. This control can confirm specificity by demonstrating signal elimination when the antibody is blocked .

• Western blot analysis: Running samples known to express or lack K15, such as specific epithelial tissue lysates, alongside molecular weight markers to confirm the detection of a single band at the expected molecular weight (approximately 55 kDa for K15) .

• Positive and negative tissue controls: Testing the antibody on tissues with known K15 expression patterns (e.g., hair follicle bulge regions as positive controls) and tissues without K15 expression (e.g., non-epithelial tissues as negative controls) .

• siRNA knockdown verification: In cell culture systems, comparing antibody staining patterns between wild-type cells and those with K15 expression silenced through siRNA approaches.

• Cross-comparison with different antibody clones: Utilizing multiple antibodies targeting different epitopes of K15 to confirm consistent staining patterns and expression profiles.

This systematic validation approach ensures that experimental results are attributed to specific K15 detection rather than non-specific binding or cross-reactivity.

What species reactivity can be expected with Cytokeratin 15 antibodies?

The species reactivity profile of Cytokeratin 15 antibodies varies depending on the specific clone and the epitope it recognizes. For the MA5-11344 monoclonal antibody (clone LHK15), documented reactivity includes:

• Human

• Mouse

• Rat

• Bovine

• Non-human primate

This broad cross-species reactivity makes this particular antibody valuable for comparative studies across different model organisms. The cross-reactivity stems from the high degree of sequence conservation in the C-terminal region of K15 across mammalian species. Researchers can reference the following UniProt IDs for sequence comparison:

• Human: P19012

• Mouse: Q61414

• Rat: Q6IFV3

When planning experiments involving less common model organisms, researchers should conduct preliminary validation studies to confirm antibody reactivity before proceeding with full-scale experiments.

What are the optimal parameters for using Cytokeratin 15 antibodies in different applications?

Optimizing experimental parameters is essential for obtaining reliable and reproducible results with Cytokeratin 15 antibodies. Here are application-specific recommendations:

For Western Blotting:

• Sample preparation: Total protein extraction with detergents suitable for membrane proteins

• Protein loading: 10-30 μg of total protein per lane

• Blocking solution: 5% non-fat dry milk or 3-5% BSA in TBST

• Primary antibody dilution: 1:200-1:1000 (clone-dependent)

• Incubation: Overnight at 4°C

• Detection system: HRP-conjugated secondary antibody with enhanced chemiluminescence

• Positive control: Epithelial tissue lysates (skin, kidney)

For Immunohistochemistry (IHC-P):

• Fixation: 10% neutral buffered formalin

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Blocking: 5-10% normal serum from secondary antibody host species

• Primary antibody dilution: 1:50-1:200

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Detection: Polymer-based detection systems or avidin-biotin complex methods

• Counterstain: Hematoxylin for nuclei visualization

For Immunocytochemistry/Immunofluorescence (ICC/IF):

• Fixation: 4% paraformaldehyde (10-15 minutes)

• Permeabilization: 0.1-0.5% Triton X-100

• Blocking: 5-10% normal serum in PBS with 0.1% Tween-20

• Primary antibody dilution: 1:100-1:500

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Secondary antibody: Fluorophore-conjugated antibodies (Alexa Fluor series)

• Nuclear counterstain: DAPI or Hoechst

These parameters should be further optimized based on the specific experimental model and research questions.

How do different Cytokeratin 15 antibody clones compare in epitope recognition and performance?

Different antibody clones recognize distinct epitopes within the Cytokeratin 15 protein, leading to variations in performance across applications and experimental conditions:

LHK15 clone (e.g., MA5-11344):

• Epitope: C-terminal region of human cytokeratin 15 (17-mer synthetic peptide)

• Strengths: Broad species reactivity (human, mouse, rat, bovine, non-human primate)

• Applications: Effective in ICC/IF, IHC-P, and Western blot

• Characteristics: Particularly useful for stem cell identification in hair follicle bulge regions

C8/144B clone:

• Epitope: Different region from LHK15

• Strengths: High specificity for human samples

• Applications: Particularly effective in IHC-P of clinical specimens

• Characteristics: Often used in diagnostic pathology for identifying specific epithelial populations

EPR1614Y clone:

• Epitope: Recombinant fragment within human KRT15

• Strengths: Rabbit monoclonal with high affinity

• Applications: Superior performance in Western blotting and IHC-P

• Characteristics: Lower background staining in certain tissue types

When selecting between clones, researchers should consider several factors including the specific application, species of interest, fixation method, and whether co-staining with other antibodies is planned. Preliminary testing of multiple clones on relevant experimental samples is recommended to identify the optimal antibody for specific research requirements.

What are the best approaches for using Cytokeratin 15 antibodies in stem cell research?

Cytokeratin 15 (K15) serves as an important marker for epithelial stem cells, particularly in the hair follicle bulge region. Researchers employing K15 antibodies in stem cell studies should consider these methodological approaches:

• Co-localization studies: Combining K15 antibodies with other stem cell markers (such as CD34, Lgr5, or Sox9) in multiplexed immunofluorescence can provide more comprehensive identification of stem cell populations. This approach requires careful antibody panel design to avoid species cross-reactivity and spectral overlap.

• Lineage tracing: K15 antibodies can be used to validate genetic lineage tracing models that utilize K15 promoter-driven reporter systems. This combines antibody staining with detection of reporter proteins to confirm the specificity of K15-expressing cell populations.

• Flow cytometry applications: Optimizing K15 antibody staining for flow cytometry requires special permeabilization protocols for accessing this intracellular marker while maintaining cell viability. A recommended approach includes:

  • Fixation with 0.5-2% paraformaldehyde

  • Permeabilization with 0.1% saponin or 90% methanol

  • Blocking with 2% BSA

  • Primary antibody incubation for 45-60 minutes

  • Fluorophore-conjugated secondary antibody detection

• 3D culture systems: When studying K15-positive cells in organoids or 3D culture systems, modified staining protocols with extended antibody incubation times (24-48 hours) and increased permeabilization may be necessary for complete tissue penetration.

• Single-cell analysis integration: Correlating K15 antibody staining patterns with single-cell RNA sequencing data can provide powerful insights into stem cell heterogeneity. This requires careful cell sorting of K15-positive populations followed by molecular profiling.

These methodological considerations enable researchers to leverage K15 antibodies effectively in identifying, isolating, and characterizing epithelial stem cell populations.

How can researchers troubleshoot cross-reactivity issues with Cytokeratin 15 antibodies?

Cross-reactivity can significantly impact experimental outcomes when working with Cytokeratin 15 antibodies. To address this common challenge, researchers should implement the following troubleshooting strategies:

• Identify potential cross-reactive keratins: Due to the structural similarity between keratin family members, cross-reactivity with other keratins (particularly other type I keratins) may occur. Researchers should consult sequence alignments to identify regions of high homology between K15 and other keratins that might lead to cross-reactivity .

• Optimize antibody concentration: Titrating the primary antibody can significantly reduce non-specific binding. Testing a range of dilutions (typically 1:50 to 1:1000) and selecting the concentration that provides the best signal-to-noise ratio is recommended.

• Modify blocking procedures: Enhancing blocking steps can minimize non-specific antibody binding:

  • Increasing blocking duration (2-4 hours)

  • Using combination blockers (e.g., 5% normal serum plus 1-3% BSA)

  • Adding 0.1-0.3% Triton X-100 to blocking solutions for better penetration

• Incorporate absorption controls: Pre-incubating the antibody with the immunizing peptide or recombinant K15 protein can confirm specificity. Signal elimination in this control indicates specific antibody binding .

• Evaluate alternative detection systems: Switching between different detection systems (e.g., from HRP-DAB to fluorescence-based detection) may help distinguish true signal from background staining.

• Consider knockout/knockdown controls: When available, samples from K15 knockout models or cells with K15 expression silenced through siRNA provide definitive negative controls to evaluate potential cross-reactivity.

• Use alternative fixation methods: Different fixatives affect epitope preservation differently. If cross-reactivity persists, testing alternative fixation protocols (e.g., methanol vs. paraformaldehyde) may improve specificity.

By systematically addressing these aspects, researchers can significantly improve the specificity of K15 antibody staining and reduce ambiguity in their experimental results.

What developability parameters should researchers consider when evaluating Cytokeratin 15 antibodies?

Evaluating the developability profile of antibodies, including those targeting Cytokeratin 15, involves assessing several critical parameters that influence experimental reproducibility and reliability:

• Colloidal properties:

  • Aggregation propensity under different storage conditions

  • Self-interaction tendencies that may affect solution behavior

  • Hydrophobicity profiles that influence solubility

  • Viscosity characteristics relevant for high-concentration applications

• Stability parameters:

  • Thermal stability assessed through differential scanning calorimetry (DSC) or differential scanning fluorimetry (DSF)

  • pH stability across physiologically relevant ranges

  • Freeze-thaw stability for repeated experimental use

  • Long-term storage stability at 4°C and -20°C

• Post-translational modifications (PTMs):

  • Glycosylation patterns that may influence recognition and binding

  • Deamidation sites that could affect activity over time

  • Oxidation susceptibility that impacts long-term stability

  • Fragmentation/clipping points that result in partial antibody degradation

• Binding characteristics:

  • Affinity measurements through surface plasmon resonance (SPR)

  • On/off rates that influence experimental kinetics

  • Epitope specificity assessment through competitive binding assays

  • Cross-reactivity profiling against related proteins

These parameters can be evaluated using small amounts of purified antibody material (100 μg to ~1 mg) through an array of analytical techniques, including:

• Size exclusion chromatography (SEC) for aggregation assessment

• Hydrophobic interaction chromatography (HIC) for hydrophobicity profiling

• Capillary isoelectric focusing (cIEF) for charge heterogeneity analysis

• Biolayer interferometry (BLI) for binding kinetics determination

Implementing this comprehensive characterization approach enables researchers to select antibodies with optimal properties for their specific applications and experimental conditions.

What controls are essential when using Cytokeratin 15 antibodies in research applications?

Proper experimental controls are fundamental to generating reliable and interpretable results with Cytokeratin 15 antibodies. Researchers should incorporate the following control types:

• Antibody specificity controls:

  • Blocking peptide control: Pre-incubating the antibody with the immunizing peptide (such as the 17-mer synthetic peptide from the C-terminus of human cytokeratin 15) should eliminate specific staining in Western blot and immunohistochemistry applications .

  • Isotype control: Using an irrelevant antibody of the same isotype, host species, and concentration to evaluate non-specific binding.

  • Absorption control with recombinant protein: Pre-absorbing the antibody with purified recombinant K15 protein to demonstrate specificity.

• Sample-related controls:

  • Positive tissue controls: Including samples known to express K15 (such as skin sections with hair follicles) to confirm detection sensitivity.

  • Negative tissue controls: Including samples known to lack K15 expression (such as non-epithelial tissues) to evaluate background staining.

  • Genetic controls: When available, using tissues or cells from K15 knockout models or after K15 knockdown.

• Technical controls:

  • Secondary antibody only: Omitting primary antibody to assess background from the detection system.

  • Concentration gradient: Testing multiple antibody dilutions to determine optimal signal-to-noise ratio.

  • Fluorescence controls: Including single-stained samples when performing multiplexed immunofluorescence to account for spectral overlap.

• Validation controls:

  • Cross-method validation: Confirming K15 expression using orthogonal methods (e.g., Western blot, RT-PCR, mass spectrometry).

  • Cross-antibody validation: Using different antibody clones targeting distinct K15 epitopes to verify staining patterns.

  • Functional validation: Correlating K15 expression with expected biological characteristics or behaviors.

How can researchers optimize immunohistochemical staining protocols for Cytokeratin 15 in different tissue types?

Optimizing immunohistochemical (IHC) staining protocols for Cytokeratin 15 requires tissue-specific considerations due to varying epitope accessibility, fixation effects, and endogenous protein levels. The following optimization strategies are recommended:

• Tissue-specific antigen retrieval optimization:

  Tissue Type	Recommended Antigen Retrieval Method	Buffer	Duration
  Skin	Heat-induced epitope retrieval	Citrate (pH 6.0)	20 min
  Hair follicles	Heat-induced epitope retrieval	EDTA (pH 9.0)	30 min
  Oral mucosa	Pressure cooker	Citrate (pH 6.0)	10 min
  Esophagus	Steam retrieval	EDTA (pH 8.0)	25 min
  Frozen sections	Often not required	-	-

• Fixation considerations:

  • For formalin-fixed tissues, fixation time significantly impacts K15 antigen preservation. Limit fixation to 24-48 hours for optimal results.

  • For frozen sections, post-fixation with 2-4% paraformaldehyde (10 minutes) maintains tissue morphology while preserving K15 antigenicity.

  • Acetone fixation (10 minutes at -20°C) provides an alternative for delicate tissues with superior epitope preservation.

• Signal amplification strategies for low-expressing tissues:

  • Tyramide signal amplification (TSA) can enhance detection sensitivity 10-100 fold

  • Polymer-based detection systems offer superior sensitivity compared to traditional ABC methods

  • Extended primary antibody incubation (overnight at 4°C) improves signal in tissues with low K15 expression

• Background reduction techniques:

  • Pre-treatment with 3% hydrogen peroxide (10 minutes) to block endogenous peroxidase

  • Avidin-biotin blocking for tissues with high endogenous biotin (liver, kidney)

  • 0.1-0.3% Sudan Black B treatment (10 minutes) to reduce autofluorescence in aged tissues

• Tissue-specific antibody dilution optimization:

  Tissue Type	Suggested Initial Dilution Range	Incubation Conditions
  Skin	1:100-1:200	1 hour at RT or overnight at 4°C
  Oral epithelium	1:50-1:100	2 hours at RT
  Esophagus	1:100-1:200	Overnight at 4°C
  Sweat glands	1:50-1:100	2 hours at RT
  Frozen sections	1:200-1:500	1 hour at RT

By systematically optimizing these parameters based on the specific tissue type and experimental goals, researchers can achieve consistent and specific K15 staining across diverse sample types.

What approaches can researchers use to evaluate batch-to-batch consistency in Cytokeratin 15 antibody performance?

Ensuring batch-to-batch consistency is critical for long-term research projects involving Cytokeratin 15 antibodies. Researchers should implement the following systematic approach to evaluate and document antibody performance across different lots:

• Standard reference sample testing:

  • Maintain a panel of reference samples (cell lysates, tissue sections) with known K15 expression levels

  • Test each new antibody lot against these standards using consistent protocols

  • Document staining intensity, pattern, and background for comparative analysis

• Quantitative assessment methods:

  • Western blot band intensity quantification using densitometry

  • Flow cytometry mean fluorescence intensity (MFI) measurement

  • Digital image analysis of immunohistochemical staining using standardized acquisition parameters and analysis algorithms

• Critical quality attribute (CQA) assessment:

  Quality Attribute	Analytical Method	Acceptance Criteria
  Specificity	Western blot	Single band at expected MW (55 kDa)
  Titer/Potency	Dilution series	EC50 within 20% of reference lot
  Background	Negative control staining	Signal-to-noise ratio >5:1
  Species cross-reactivity	Multi-species panel testing	Consistent reactivity pattern
  Epitope recognition	Peptide competition	>90% signal reduction

• Stability monitoring program:

  • Aliquot reference lots for long-term storage under standardized conditions

  • Periodically test stored aliquots to establish stability profiles

  • Compare new lots against both fresh and aged reference standards

• Documentation and trending analysis:

  • Maintain comprehensive records of lot testing results

  • Implement statistical process control (SPC) charting to detect gradual performance drift

  • Document acceptable performance ranges for critical applications

• Advanced analytical characterization:

  • Surface plasmon resonance (SPR) for binding kinetics assessment

  • Mass spectrometry for evaluating antibody sequence consistency

  • Circular dichroism (CD) spectroscopy for secondary structure analysis

By implementing this systematic approach to batch qualification, researchers can minimize experimental variability due to antibody lot changes and ensure reliable, reproducible results throughout extended research projects.

How can Cytokeratin 15 antibodies be effectively used in multiplexed imaging studies?

Multiplexed imaging with Cytokeratin 15 antibodies enables simultaneous visualization of K15 alongside other markers, providing rich contextual information about tissue architecture and cell populations. Researchers can implement the following approaches for successful multiplexed studies:

• Antibody panel design considerations:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • Ensure compatible fixation requirements across all target epitopes

  • Validate each antibody individually before combining into multiplexed panels

  • Consider K15 antibody clone LHK15 for broad species compatibility

• Sequential staining protocols:
  For markers requiring incompatible detection methods:

  • Apply first primary antibody and complete detection

  • Apply chemical stripping using glycine-SDS buffer (pH 2.0)

  • Validate complete removal of first antibody

  • Proceed with second primary antibody and detection

• Spectral unmixing approaches:

  • Employ multispectral imaging platforms (e.g., Vectra, Mantra)

  • Create spectral libraries for each fluorophore and autofluorescence

  • Apply computational unmixing algorithms to separate overlapping signals

  • Include single-stained controls for accurate spectral signatures

• Compatible antigen retrieval optimization:

  Marker Combination	Recommended Universal Retrieval Method
  K15 + CD34 + Lgr5	EDTA buffer (pH 8.0), pressure cooker, 10 min
  K15 + Ki67 + p63	Citrate buffer (pH 6.0), microwave, 20 min
  K15 + SOX9 + K14	Tris-EDTA (pH 9.0), water bath, 30 min
  K15 + CD200 + Integrin-α6	DAKO Target Retrieval Solution, pressure cooker, 10 min

• Advanced multiplexing technologies:

  • Tyramide signal amplification (TSA) with sequential antibody stripping

  • Metal-tagged antibodies with mass cytometry (CyTOF) for highly multiplexed analysis

  • DNA-barcoded antibodies with sequential fluorescence in situ hybridization (seqFISH)

  • Quantum dot-conjugated secondary antibodies for improved spectral separation

• Image analysis and quantification:

  • Use machine learning algorithms for automated cell classification

  • Apply spatial analysis to quantify cellular relationships and tissue organization

  • Implement nuclear segmentation followed by cytoplasmic signal quantification

  • Utilize colocalization coefficients to quantify marker overlap

These approaches enable researchers to generate complex phenotypic profiles of K15-expressing cells within their tissue microenvironment, providing deeper insights into stem cell biology, tissue homeostasis, and disease pathology.

What is the role of Cytokeratin 15 in epithelial stem cell research and how can antibodies facilitate these studies?

Cytokeratin 15 serves as a crucial marker in epithelial stem cell research, with K15 antibodies playing a central role in identifying and characterizing these important cell populations:

• Hair follicle bulge stem cells:
  K15 expression strongly correlates with the hair follicle bulge region, which contains epithelial stem cells responsible for hair follicle cycling and epidermal wound repair. K15 antibodies enable precise localization of these stem cell populations within complex skin architecture, facilitating studies on:

  • Hair follicle regeneration cycles

  • Wound healing contributions

  • Age-related changes in stem cell reservoirs

  • Response to therapeutic interventions

• Lineage tracing methodologies:
  Combining K15 antibody labeling with genetic lineage tracing approaches provides comprehensive insights into stem cell dynamics:

  • Initial identification of stem cell populations using K15 immunostaining

  • Confirmation of K15 promoter activity in transgenic reporter models

  • Long-term fate mapping of K15-expressing cells during tissue homeostasis and repair

  • Quantification of stem cell contribution to different lineages

• Cancer stem cell identification:
  K15 antibodies contribute to understanding the role of epithelial stem cells in cancer initiation and progression:

  • Identification of K15-positive tumor-initiating cells

  • Correlation between K15 expression and tumor aggressiveness

  • Evaluation of stem cell marker co-expression (K15/CD34/SOX9)

  • Assessment of chemotherapy resistance in K15-positive cell populations

• Methodological approaches for stem cell isolation:
  K15 antibodies facilitate the isolation and characterization of epithelial stem cells through:

  • Fluorescence-activated cell sorting (FACS) using permeabilized cells labeled with K15 antibodies

  • Magnetic-activated cell sorting (MACS) following cell permeabilization

  • Laser capture microdissection of K15-positive regions identified by immunostaining

  • Live-cell surface marker combinations correlated with K15 expression

• 3D culture systems and organoids:
  K15 antibodies provide valuable tools for characterizing stem cell behavior in advanced culture systems:

  • Validation of stem cell identity in 3D organoid cultures

  • Monitoring differentiation dynamics through K15 expression changes

  • Correlating K15 expression with organoid-forming efficiency

  • Assessing the impact of microenvironmental factors on K15-positive stem cell maintenance

By leveraging K15 antibodies in these diverse research applications, investigators can gain deeper insights into the fundamental biology of epithelial stem cells and their roles in tissue homeostasis, regeneration, and disease.

What future directions are emerging in Cytokeratin 15 antibody applications?

The field of Cytokeratin 15 antibody applications continues to evolve, with several emerging trends and methodologies poised to expand research capabilities:

• Integration with spatial transcriptomics: Combining K15 antibody labeling with spatial transcriptomic technologies allows researchers to correlate protein expression with comprehensive gene expression profiles in a spatially resolved manner. This integration provides unprecedented insights into the molecular heterogeneity of K15-positive cell populations within their native tissue context.

• Engineered recombinant antibody fragments: Development of single-chain variable fragments (scFvs) and nanobodies against K15 epitopes promises improved tissue penetration, reduced background, and compatibility with super-resolution microscopy techniques. These smaller binding molecules can access restricted epitopes and enable higher-density labeling.

• Live-cell imaging applications: Advances in cell-permeable fluorescently conjugated antibody fragments or fluorescent protein tags may enable dynamic monitoring of K15 expression in living systems, facilitating studies of epithelial stem cell behavior in real-time during differentiation or wound healing processes.

• Therapeutic targeting applications: K15 antibody derivatives may find applications in targeted delivery of therapeutics to specific epithelial stem cell populations, with potential applications in regenerative medicine, wound healing, and cancer treatment.

• Artificial intelligence integration: Advanced image analysis algorithms and machine learning approaches will enhance the extraction of quantitative data from K15 antibody staining, enabling more sophisticated spatial analysis and cell classification in complex tissues.

• High-dimensional cytometry: Integration of K15 antibodies into CyTOF (mass cytometry) and highly multiplexed flow cytometry panels will facilitate comprehensive phenotyping of epithelial stem cell populations with simultaneous measurement of dozens of additional markers.

As technology continues to advance, Cytokeratin 15 antibodies will remain essential tools in epithelial biology research, with expanding applications across basic science, translational research, and potentially therapeutic development.